$AII

Citizens raises American Integrity Insurance stock price target on light catastrophe losses

Citizens raised its price target for American Integrity Insurance Group (AII) to $29.00 from $26.00, citing light catastrophe losses and maintaining a Market Outperform rating. The stock trades near its 52-week high at $26.77. The firm expects Q3 2026 results to reflect minimal domestic catastrophe losses, though book values may decline due to rising interest rates. AII reported Q2 2026 earnings of $1.78 per share, beating estimates, with revenue of $115.17 million.

Original reporting
Published Oct 12, 2026, 9:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 9:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AII
Bullish
medium confidence
Mentioned
$AII
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AIIBullishLow
01

Why it matters

Analyst upgrades may provide a small catalyst, but no new company‑specific data are disclosed.

02

Market read

Limited relevance; price‑target change is a minor catalyst for a small insurer.

03

Timing

none

Relevance 4/10Novelty 2/10Timing: none

Background

The article recaps AII's Q2 2026 earnings and recent analyst price‑target upgrades.

Company-level read

Ticker impact

$AIIBullishMedium confidence
Context

Citizens raised its price target on AII to $29 from $26 and reiterated an Outperform rating.

Expected impact

likely modest upward pressure as investors price in the higher target

Evidence & confidence

Target raise is a fresh analyst action, but the underlying earnings data are old, limiting impact.

Key entities

  • Citizens

    Raised price target on AII

Related articles

$AIIMedAI 8/10

American Integrity Insurance (AII) Q2 2026 Earnings Call Transcript

American Integrity Insurance (AII) reported Q2 2026 earnings with net income up 24.2% to $34.1M, diluted EPS up to $1.74, and gross premiums written up 13.8% to $326.6M. Policies in force grew 15.7% YoY to 461,714. The company expanded in the Tri-County region and middle-aged home segments, improved its combined ratio to 63.4%, and deployed $200M into fixed income securities.

$AIIMed

American Integrity Insurance Group Q2 Earnings Call Highlights

American Integrity Insurance Group (NYSE:AII) reported Q2 growth and underwriting results on an earnings call. Gross premiums written rose 13.8% to $326.6M and net premiums earned rose 58.2% to $104.7M. The combined ratio improved to 63.4% from 72.9%. Management reaffirmed annual catastrophe reinsurance costs of $430M to $440M and deployed nearly $200M into fixed-income securities.

$AIIMed

American Integrity Insurance Group, Inc. Reports Second Quarter 2026 Results

American Integrity Insurance Group, Inc. (AII) filed an SEC Form 8-K — Results of Operations and Financial Condition. American Integrity Insurance Group, Inc. Reports Second Quarter 2026 Results 43K voluntary new business policies sold in the quarter, a record for American Integrity, up 54% vs. the second quarter of 2025 and 44% vs. the first quarter of 2026 $46.4 million of income before income

$AZNHigh

A lung cancer trial found 21.1 months’ median survival with two drugs, versus 12.7 with one.

AstraZeneca's trial showed IMFINZI plus tarlatamab-dlle improved median survival to 21.1 months vs. 12.7 months with IMFINZI alone in extensive-stage small cell lung cancer. The combination reduced death risk by 58% and progression risk by 66%. Results were consistent across subgroups, including brain metastases. AstraZeneca aims to redefine treatment standards. Data presented at ESMO Congress 2026.

$AMGNHigh

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Amgen (AMGN) announced that IMDELLTRA® combined with AstraZeneca's IMFINZI® reduced the risk of death by 58% in extensive stage small cell lung cancer (ES-SCLC) patients. Median overall survival increased to 21.1 months from 12.7 months with IMFINZI alone. The Phase 3 DeLLphi-305 study results were presented at ESMO Congress 2026 and published in The New England Journal of Medicine.